Print Page   |   Contact Us   |   Sign In   |   Join Now!
News & Press: Industry Update

Louisiana Health Alert Message: Diagnosing and Managing Shigella

Monday, April 24, 2017  
Posted by: Nicole Turner
Share |

 

Public Health Alert 

Louisiana Health Alert Message: Diagnosing and Managing Shigella

 

CDC Recommendations for Diagnosing and Managing Shigella Strains with Possible Reduced Susceptibility to Ciprofloxacin


Summary 
This Health Advisory describes the identification of emerging Shigella strains with elevated minimum inhibitory concentration values for ciprofloxacin and outlines new recommendations for clinical diagnosis, management, and reporting, as well as new recommendations for laboratories and public health officials. Current interpretive criteria provided by the Clinical and Laboratory Standards Institute (CLSI) categorize these strains as susceptible to ciprofloxacin, which is a fluoroquinolone antibiotic and a key agent in the management of Shigella infections. 
However, recent data from the Centers for Disease Control and Prevention (CDC) and state and local public health partners show that these strains often have a quinolone resistance gene that may lead to clinically significant reduced susceptibility to fluoroquinolone antibiotics. Clinicians treating patients with multidrug-resistant shigellosis for whom antibiotic treatment is indicated should avoid prescribing fluoroquinolones if the ciprofloxacin MIC is 0.12 μg/mL or higher even if the laboratory report identifies the isolate as susceptible, and should work closely with their clinical microbiology laboratory and infectious disease specialists to determine appropriate antimicrobial therapy. 
Shigellosis is a nationally notifiable condition, and all cases of shigellosis should be reported to local health departments.

Background 
CDC has identified an increase in Shigella isolates in the United States with minimum inhibitory concentration (MIC) values of 0.12–1 μg/mL for the fluoroquinolone antibiotic ciprofloxacin. Preliminary data suggest that all Shigella isolates with ciprofloxacin MICs in this range for which results are available harbor at least one quinolone resistance gene known to confer reduced susceptibility in enteric bacteria. Shigella isolates without a quinolone resistance gene typically have a ciprofloxacin MIC of ≤0.015 μg/mL. Current CLSI criteria categorize Shigella isolates with a ciprofloxacin MIC of ≤1 μg/mL as susceptible to ciprofloxacin (1).

CDC does not yet know whether fluoroquinolone treatment of a Shigella infection with a ciprofloxacin MIC of 0.12–1 μg/mL is associated with a worse clinical outcome for the patient or if such treatment increases the risk of transmission to other individuals. In Salmonella isolates, ciprofloxacin MICs of 0.12–1 μg/mL have been associated with reduced susceptibility, prolonged clinical illness, and treatment failures and are now categorized by CLSI as intermediate or resistant to ciprofloxacin in Salmonella species. 
Fluoroquinolone resistance is of particular concern given that data from the National Antimicrobial Resistance Monitoring System indicate that many Shigella isolates with a quinolone resistance gene also are resistant to many other commonly used treatment agents, such as azithromycin, trimethoprim-sulfamethoxazole, amoxicillin-clavulanic acid, and ampicillin. This susceptibility profile may encourage clinicians to prescribe fluoroquinolone antibiotics to patients who require treatment.

Rising fluoroquinolone MIC values among Shigella isolates may be related to the emergence of plasmid-mediated quinolone resistance (PMQR) genes in Shigella species in the United States. Shigella strains harboring PMQR genes were identified earlier this year following whole genome sequencing of isolates from a multistate outbreak of multidrug-resistant Shigella flexneri infections predominantly affecting adult men, many of whom identify as men who have sex with men, according to epidemiologic data collected by CDC’s Shigella program as part of outbreak response. PMQR genes have also been identified in sporadic cases of Shigella sonnei. Plasmid-mediated resistance genes are of particular concern because of their ability to spread between bacteria and their ability to promote chromosomal mutations conferring quinolone resistance, potentially resulting in rapid spread of fluoroquinolone resistance within or between populations of bacteria. The prevalence of PMQR genes among all U.S. Shigella isolates is currently unknown.

Any patient with a Shigella infection could carry a strain harboring a quinolone resistance gene with a ciprofloxacin MIC of 0.12–1 μg/mL. 


The emergence of Shigella species with ciprofloxacin MICs of 0.12–1 μg/mL and their association with quinolone resistance genes raises the following concerns:

·Fluoroquinolone treatment of Shigella infection with a strain harboring a quinolone resistance  gene may be less effective and may increase the risk of a more severe clinical course for the  individual (e.g., increased duration or severity of symptoms, increased need for hospitalization  or admission to an intensive care unit,  increased length of hospitalization, or increased risk of  death).

·Fluoroquinolone treatment of Shigella infection with a strain harboring a quinolone resistance  gene also may increase the risk of secondary cases, if the treatment prolongs the duration or  increases the quantity of organisms shed in the stool, given the very low infectious dose  required for transmission of Shigella  bacteria. 

RECOMMENDATIONS FOR CLINICIANS 
Diagnosis

·Order stool culture for patients suspected of having a Shigella infection to obtain isolates for  antimicrobial susceptibility testing.

·Culture-independent diagnostic testing does not provide an isolate and therefore cannot be  used to assess susceptibility.

·Order antimicrobial susceptibility testing when ordering stool culture for Shigella.

·When antimicrobial susceptibility testing is performed by broth microdilution, request  ciprofloxacin testing that includes dilutions of 0.12 μg/mL or lower.

·Even when treatment is not indicated, identifying patients with drug-resistant infections (i.e.,  ordering susceptibility testing) will help to inform public health management, such as when to  return to work, school, and group settings. 

Management

·Do not routinely prescribe antibiotic therapy for Shigella infection. Instead, reserve antibiotic  therapy for patients for whom it is clinically indicated or when public health officials advise  treatment in an outbreak setting.

·Shigellosis is generally a self-limited infection lasting 5-7 days.

·Unnecessary treatment with antibiotics promotes resistance.

·Treatment can shorten the duration of some illnesses, though typically only by 1-2 days.

·Empiric treatment with an antibiotic to which the organism is resistant may worsen symptoms  or prolong the duration of shedding of the organism.

·If empiric treatment is clinically indicated before antimicrobial susceptibility results are  available, refer to recent hospital, clinical laboratory, or public health agency antibiograms.

·Antibiotic treatment is recommended for patients who are immunocompromised or who  develop severe illness (e.g., patients requiring hospitalization, those with invasive disease, or  those with complications).

·Local or state health officials may advise antibiotic treatment to mitigate or prevent outbreaks  in certain settings (e.g., childcare, food handling).

·When antibiotic treatment is indicated, tailor antibiotic choice to antimicrobial susceptibility  results as soon as possible with special attention given to the MIC for fluoroquinolone  antibiotics.

·Avoid prescribing fluoroquinolones if the ciprofloxacin MIC is 0.12 μg/mL or higher even if the  laboratory report identifies the isolate as susceptible.

·Know the potential risks of fluoroquinolone treatment of Shigella infections with ciprofloxacin  MICs in this range, including possible treatment failure and increased risk of secondary  transmission.

·The interpretation of MIC values varies for the different fluoroquinolone antibiotics; if  susceptibility results are reported for a fluoroquinolone other than ciprofloxacin, contact the  microbiology laboratory for assistance with interpretation.

·If MIC values are not reported to the clinician with susceptibility results, consider contacting  the microbiology laboratory where the susceptibility testing was performed to determine the  ciprofloxacin MIC value before treating a patient with a fluoroquinolone agent. Some  susceptibility testing methods do not produce a       MIC value; the impact of a quinolone  resistance gene on test results by other methods (e.g., disk diffusion) is not yet known.

·Consult an infectious disease specialist for cases where the Shigella isolate is resistant to  multiple antibiotics and appropriate treatment is unclear.

·Obtain follow-up stool cultures in shigellosis patients who have continued or worsening  symptoms despite antibiotic therapy.

·Consult your local or state health department for guidance on when patients may return to  childcare, school, or work.

·Counsel patients with active diarrhea on how they can prevent spreading the infection to  others, regardless of whether antibiotic treatment is prescribed.

·Wash hands with soap and water for at least 20 seconds, especially after using the toilet,  after handling a soiled diaper, and before eating.

·Avoid preparing food for others, when possible.

·Children with active diarrhea should not attend childcare, school, or group activities while they  are ill.

·Wait to have sex (vaginal, anal, and oral) for two weeks after you no longer have diarrhea.  Use safe sex practices for several weeks after resuming sex, because Shigella bacteria may  still be in stool for several weeks. 

Reporting

·Shigellosis is a nationally notifiable condition. Report all cases of shigellosis should be  reported immediately to Louisiana Infectious Disease Epidemiology at 1-800-256-2748.

·Clinicians who identify a patient with shigellosis and a ciprofloxacin MIC of 0.12–1 μg/mL  should include this finding along with other information regarding the case to their local health  department to facilitate further testing of the isolate. 

RECOMMENDATIONS FOR LABORATORIES

·Know that a Shigella isolate with a ciprofloxacin MIC of 0.12–1 μg/mL may be associated with  the presence of a quinolone resistance gene.

·Test Shigella isolates using susceptibility panels that include 0.12, 0.25, and 0.5 μg/mL  dilutions for ciprofloxacin, when using a commercially available automated system (such as  BD Phoenix, MicroScan, Vitek 2, or similar system) for susceptibility testing.

·Include MIC values for fluoroquinolone agents in the susceptibility testing report for Shigella  isolates.

·Report all findings of strains of Shigella with a ciprofloxacin MIC of 0.12–1 μg/mL to the state  public health laboratory, and submit isolates to it to facilitate further phenotypic and genetic  testing. 

RECOMMENDATIONS FOR PUBLIC HEALTH OFFICIALS

·Know that a Shigella isolate with a ciprofloxacin MIC of 0.12–1 μg/mL may be associated with  the presence of a quinolone resistance gene.

·Contact CDC at EntericBacteria@cdc.gov if you receive reports of patients with Shigella  infection and possible fluoroquinolone treatment failure.

·Submit Shigella isolates with a ciprofloxacin MIC of 0.12–1 μg/mL to the state public health  laboratory for whole genome sequencing, if possible. If the state laboratory does not have  capacity to sequence the isolate, please notify CDC at EntericBacteria@cdc.gov

What CDC is Doing 
CDC is working with state and local public health departments and clinical partners to investigate if clinical outcomes are worse for patients infected with Shigella strains harboring a quinolone resistance gene who receive ciprofloxacin treatment.

·CDC has notified representatives at the U.S. Food and Drug Administration and CLSI, who  will review CDC’s findings to determine whether a change to the susceptible range of MIC  values for ciprofloxacin in Shigella is warranted.

·CDC will continue to monitor trends in antimicrobial susceptibility of Shigella isolates and will  perform genetic testing on select strains with ciprofloxacin MICs of 0.12–1 μg/mL or higher to  confirm the presence and type of quinolone resistance genes. 

For More Information

·For general information about Shigella or shigellosis, visit https://www.cdc.gov/shigella/.

·For technical information about Shigella or shigellosis, including information about national  surveillance and other educational resources for medical and public health professionals,  visit https://www.cdc.gov/shigella/resources.html.

·For information about prevention and control of shigellosis, including recommendations for  men who have sex with men, visit https://www.cdc.gov/shigella/prevention-control.html.

·For more information about the serious public health threat posed by antimicrobial resistant  Shigella, refer to “Antibiotic Resistance Threats in the United States, 2013” available  at https://www.cdc.gov/drugresistance/threat-report-2013/pdf/ar-threats-2013-508.pdf

·For more information about ciprofloxacin and azithromycin-nonsusceptible shigellosis in the  United States, refer to previous Health Alert Network Advisory 379  at https://emergency.cdc.gov/han/han00379.asp.

·For specific inquiries related to this Health Advisory, email EntericBacteria@cdc.gov

Reference 
1. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing. 27th ed. CLSI supplement M100. Wayne, PA: Clinical and Laboratory Standards Institute; 2017. 

In the state of Louisiana and nationally, Shigellosis is a notifiable condition. Report all cases of shigellosis immediately. To discuss a possible exposure, request laboratory testing, or report a suspected case, contact the Louisiana Office of Public Health at 504-568-8313 or after hours at 1-800-256-2748.

 


Copyright © 2010 Louisiana Pharmacists Association. All Rights Reserved.
620 Florida St., Suite 210 | Baton Rouge, LA 70801 | (225) 346-6883 | Fax (225) 344-1132

Association Management Software Powered by YourMembership  ::  Legal